NCT01284920View on ClinicalTrials.gov

A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

November 2, 2010

Primary Completion Date

July 12, 2012

Study Completion Date

July 2, 2014

Conditions
Prostate CancerProstate NeoplasmsCastration Resistant Prostate Cancer (CRPC)
Interventions
DRUG

MDV3100

oral

Trial Locations (7)

Unknown

Chugoku

Chūbu

Hokkaido

Kansai

Kanto

Kyusyu

Shikoku

Sponsors
All Listed Sponsors
collaborator

Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY